HCV-associated Marginal Zone Lymphoma · line 1 · Bendamustine + Rituximab (BR), 6 cycles

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	aggressive
Linked regimen	`REG-BR-STANDARD`

ID	`IND-HCV-MZL-1L-BR-AGGRESSIVE`
Type	Indication
Status	reviewed 2026-04-24 \| pending_clinical_signoff
Diseases	`DIS-HCV-MZL`
Sources	`SRC-ESMO-LYMPHOMA-2025` `SRC-NCCN-BCELL-2025`

Notes

STUB — requires clinical co-lead signoff before publication. Aggressive counterpart to IND-HCV-MZL-1L-ANTIVIRAL for two-plan output (CHARTER §2).

Used By

Algorithms

ALGO-HCV-MZL-1L - ALGO-HCV-MZL-1L

Indication

IND-HCV-MZL-POST-DAA-SURVEILLANCE - IND-HCV-MZL-POST-DAA-SURVEILLANCE

Questionnaires

QUEST-HCV-MZL-1L - HCV-associated Marginal Zone Lymphoma — first line